A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)
- Status
- COMPLETED
- Phase
- PHASE1
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
- Status
- COMPLETED
- Phase
- PHASE3
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Understanding Barriers and Facilitators to the Participation of Women Living With HIV in Clinical Trials : a Mixed-method Study (EVA)
- Status
- COMPLETED
- Phase
- N/A
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
- Status
- TERMINATED
- Phase
- PHASE3
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Merck IIT: RRP Pembro and Lenvatinib
- Status
- RECRUITING
- Phase
- PHASE2
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
- Status
- TERMINATED
- Phase
- PHASE3
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)
- Status
- COMPLETED
- Phase
- PHASE3
Sleep Trial to Prevent Alzheimer's Disease
- Status
- RECRUITING
- Phase
- PHASE2
Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
- Status
- TERMINATED
- Phase
- PHASE4